体细胞治疗是将机体细胞在体外进行各种处理后，再回输病人的治疗方式。
该生物学家拥有包括将分子导入活体细胞的纳米注射器、人工骨科材料、结核病靶标治疗和细胞芯片平台等专利。
The biologist holds patents including a cell nanoinjector that introduces molecules into living cells, artificial bone materials, targets for tuberculosis therapy and cell microarray platforms.
他说，这些药物对于实验室内的人体细胞很有效果，但是在正式成为治疗手段之前还需进行药物毒理和临床实验，而这个过程大概需要五年或更长时间。
He said that the drugs have been effective on human cells in the laboratory but that toxicology and clinical trials would be needed before it could be adopted as a treatment.
该药物能够准确的将正确的染色体数目导入每一新细胞，产生非整倍体细胞，能够用于治疗由于肿瘤抑制基因突变导致的肿瘤。
Drugs that inhibit accurate delivery of the right number of chromosomes to each new cell, resulting in aneuploidy, would be used to destroy tumors caused by mutations in the tumor suppressors.
应用推荐